In the BioHarmony Drug Report Database

"Preview" Icon

Degarelix

Firmagon (degarelix) is a protein pharmaceutical. Degarelix was first approved as Firmagon on 2008-12-24. It is used to treat prostatic neoplasms in the USA. It has been approved in Europe to treat prostatic neoplasms. The pharmaceutical is active against gonadotropin-releasing hormone receptor. Firmagon’s patents are valid until 2032-04-27 (FDA).

 

Trade Name

 

Firmagon
 

Common Name

 

degarelix
 

ChEMBL ID

 

CHEMBL415606
 

Indication

 

prostatic neoplasms
 

Drug Class

 

Hormone-release inhibiting peptides

Image (chem structure or protein)

Degarelix structure rendering